Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech HOLDRs (AMEX: BBH) -- Ignore unavailable to you. Want to Upgrade?

To: Howard Clark who wrote (2)	11/23/1999 11:18:00 PM
From: Xenogenetic	Respond to of 98

1. A good question, and one that I do not have the answer to. I would guess that ML/Amex would give you a record of the respective share prices of the underlying biotechs at the time of the HOLDR purchase. 2. Again, I don't know, but if I had to venture a guess I would imagine that Merrill would evaluate each quarterly/annually, or spontaneously, like the Dow does. I don't think an investor can change the makeup of the HOLDR short of redeeming it. That's my understanding. Telebras (TBH) was the first HOLDR that Merrill issued, and I would assume that the same rules would apply to BBH. Appalling that BBH is trading but there is no detailed information (at least from my cursory search) information on it on either ML.com or Amex.com. Nothing but a press release it seems. Sure as heck not calling Merrill, that's for sure. My phone would be ringing off the hook from Merrill's coldcallers. I am still busy fending off the fort from Smith Barney attacks during dinner. :-)